unknown node
unknown node
unknown node
unknown node
unknown node
unknown node
- unknown node
- unknown node
- unknown node
- unknown node
unknown node
unknown node
unknown node
unknown node
Hospital-acquired Infections · Case-Based Insights · Quality Control · Lab Operations
unknown node
unknown node
unknown node
unknown node
unknown node
Late MRSA screening is usually a workflow diagnosis, not an assay problem: transport cadence, batching, and result-release gates determine whether a fast assay delivers fast decisions. Measure collection-to-isolation time and pre-isolated positives to verify any fix.
Target audienceInfection Prevention, Lab Director, Operations
Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.
2026-10-06
2026-10-06
professional use
FAQ
No. This is a composite scenario assembled from common, well-described failure patterns in screening workflows. It is illustrative and does not describe a specific institution.
Universal isolation consumes isolation rooms, staffing, and patient experience. Screening aims to target precautions where they matter; if screening results arrive late, the targeting logic fails regardless of assay quality.
In the workflow pattern described, no: a validated molecular result triggers isolation, while culture runs in parallel for epidemiology and susceptibility data. Local policy and accreditation requirements always govern.
Median time from screening collection to isolation decision, paired with the proportion of positive patients already isolated when the result releases. Both move only when the whole workflow works.